Eli Lilly expands partnership with Innovent to develop oncology, immunology drugs
Source: SeekingAlpha
2026-02-08 10:33:49 ET
More on Eli Lilly, Innovent Biologics
- Eli Lilly: Positives Outweigh The Concerns
- Eli Lilly and Company 2025 Q4 - Results - Earnings Call Presentation
- Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
- President Trump unveils TrumpRx website for low-cost prescription drugs
- Eli Lilly, Novo down as Hims to offer cheaper weight-loss pill
Read the full article on Seeking Alpha
For further details see:
Eli Lilly expands partnership with Innovent to develop oncology, immunology drugs
Innovent Biologics Inc ADR
NASDAQ: IVBIY
IVBIY Trading
0.0% G/L:
$40.295 Last:
303 Volume:
$40.295 Open:
IVBIY Latest News
January 26, 2026 07:00:00 pm
Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
January 08, 2026 07:00:00 pm
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
